Difference between revisions of "ALK-rearranged renal cell carcinoma"

Jump to navigation Jump to search

ALK-rearranged renal cell carcinoma (view source)

Revision as of 21:50, 26 September 2025

7,628 bytes removed ,  21:50, 26 September 2025
fix
(fix)
 
Line 34: Line 34:


It may be abbreviated ''ALK-RCC''.
It may be abbreviated ''ALK-RCC''.
==General==
*Extremely rare.
**One case was identified in 829 consecutively screened Korean patients.<ref name=pmid24255633>{{Cite journal  | last1 = Lee | first1 = C. | last2 = Park | first2 = JW. | last3 = Suh | first3 = JH. | last4 = Nam | first4 = KH. | last5 = Moon | first5 = KC. | title = ALK-Positive Renal Cell Carcinoma in a Large Series of Consecutively Resected Korean Renal Cell Carcinoma Patients. | journal = Korean J Pathol | volume = 47 | issue = 5 | pages = 452-7 | month = Oct | year = 2013 | doi = 10.4132/KoreanJPathol.2013.47.5.452 | PMID = 24255633 }}</ref>
**A second series described 8 in 276 cases on a microarray.<ref name=pmid38039739>{{cite journal |authors=Doğan K, Onder E |title=ALK-rearranged renal cell carcinoma (ALK-RCC): Evaluation of histomorphological and immunohistochemical features by analysis of 276 renal cell carcinoma cases in Turkey |journal=Pathol Res Pract |volume=253 |issue= |pages=154951 |date=January 2024 |pmid=38039739 |doi=10.1016/j.prp.2023.154951 |url=}}</ref>
**In 2016, less than 17 cases reported.<ref name=pmid27554841>{{Cite journal  | last1 = Jeanneau | first1 = M. | last2 = Gregoire | first2 = V. | last3 = Desplechain | first3 = C. | last4 = Escande | first4 = F. | last5 = Tica | first5 = DP. | last6 = Aubert | first6 = S. | last7 = Leroy | first7 = X. | title = ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult. | journal = Pathol Res Pract | volume = 212 | issue = 11 | pages = 1064-1066 | month = Nov | year = 2016 | doi = 10.1016/j.prp.2016.07.015 | PMID = 27554841 }}</ref>
*May respond to [[ALK inhibitors]] such as alectinib<ref name=pmid29685646>{{Cite journal  | last1 = Pal | first1 = SK. | last2 = Bergerot | first2 = P. | last3 = Dizman | first3 = N. | last4 = Bergerot | first4 = C. | last5 = Adashek | first5 = J. | last6 = Madison | first6 = R. | last7 = Chung | first7 = JH. | last8 = Ali | first8 = SM. | last9 = Jones | first9 = JO. | title = Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. | journal = Eur Urol | volume = 74 | issue = 1 | pages = 124-128 | month = 07 | year = 2018 | doi = 10.1016/j.eururo.2018.03.032 | PMID = 29685646 }}</ref> or crizotinib.<ref name=pmid27554841>{{Cite journal  | last1 = Jeanneau | first1 = M. | last2 = Gregoire | first2 = V. | last3 = Desplechain | first3 = C. | last4 = Escande | first4 = F. | last5 = Tica | first5 = DP. | last6 = Aubert | first6 = S. | last7 = Leroy | first7 = X. | title = ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult. | journal = Pathol Res Pract | volume = 212 | issue = 11 | pages = 1064-1066 | month = Nov | year = 2016 | doi = 10.1016/j.prp.2016.07.015 | PMID = 27554841 }}</ref>
==Microscopic==
Features:
*Mix of morphologies - including:
**[[Papillary renal cell carcinoma]].<ref name=pmid24255633/>
**[[Renal cell carcinoma with rhabdoid morphology|Rhabdoid change]].<ref name=pmid26017874>{{Cite journal  | last1 = Kuroda | first1 = N. | last2 = Karashima | first2 = T. | last3 = Inoue | first3 = K. | last4 = Kasajima | first4 = A. | last5 = Ohe | first5 = C. | last6 = Kawakami | first6 = F. | last7 = Mikami | first7 = S. | last8 = Matsuura | first8 = K. | last9 = Moriyama | first9 = M. | title = Review of renal cell carcinoma with rhabdoid features with focus on clinical and pathobiological aspects. | journal = Pol J Pathol | volume = 66 | issue = 1 | pages = 3-8 | month = Mar | year = 2015 | doi =  | PMID = 26017874 }}</ref>
**[[Renal cell carcinoma with sarcomatoid differentiation|Sarcomatoid change]].
**"[[Unclassified renal cell carcinoma]]".
DDx:
*[[Papillary renal cell carcinoma]] - especially what used to be known as "type 2".<ref name=pmid24255633/>
*[[Unclassified renal cell carcinoma]]
*[[Renal medullary carcinoma]].
*[[Clear cell renal cell carcinoma]].<ref name=pmid38039739/>
*[[Renal mucinous tubular and spindle cell carcinoma]].<ref>{{cite journal |authors=Kai K, Tobu S, Kido S, Mikami S, Takeuchi K, Dobashi A, Togashi Y, Noguchi M, Aishima S |title=ALK rearrangement-associated renal cell carcinoma morphologically mimicking mucinous tubular and spindle cell carcinoma: a case report |journal=Diagn Pathol |volume=17 |issue=1 |pages=52 |date=June 2022 |pmid=35718773 |pmc=9206751 |doi=10.1186/s13000-022-01238-z |url=}}</ref>
==IHC==
Features:<ref>{{Cite journal  | last1 = Jeanneau | first1 = M. | last2 = Gregoire | first2 = V. | last3 = Desplechain | first3 = C. | last4 = Escande | first4 = F. | last5 = Tica | first5 = DP. | last6 = Aubert | first6 = S. | last7 = Leroy | first7 = X. | title = ALK rearrangements-associated renal cell carcinoma (RCC) with unique pathological features in an adult. | journal = Pathol Res Pract | volume = 212 | issue = 11 | pages = 1064-1066 | month = Nov | year = 2016 | doi = 10.1016/j.prp.2016.07.015 | PMID = 27554841 }}</ref>
*L-ALK +ve. ‡
*PAX8 +ve.
*Vimentin +ve (diffuse).
*CK7 +ve (focal).
*[[SMARCB1]] normal nuclear staining.{{fact}}
‡ There are different clones for ALK; they may be called ''ALK1'' (used in lymphoma) and ''L-ALK'' (used in lung cancer).  In the context of RCC, the ALK clone for lung cancer (e.g. D5F3) should be used.<ref>{{cite journal |authors=Kai K, Tobu S, Kido S, Mikami S, Takeuchi K, Dobashi A, Togashi Y, Noguchi M, Aishima S |title=ALK rearrangement-associated renal cell carcinoma morphologically mimicking mucinous tubular and spindle cell carcinoma: a case report |journal=Diagn Pathol |volume=17 |issue=1 |pages=52 |date=June 2022 |pmid=35718773 |pmc=9206751 |doi=10.1186/s13000-022-01238-z |url=}}</ref>
==Molecular==
*ALK rearrangement.
==See also==
*[[Vancouver classification]].
*[[Kidney tumours]].
*[[Lung carcinoma with ALK rearrangement]].
==References==
{{Reflist|2}}
[[Category:Kidney tumours]]
[[Category:Diagnosis]]
Summary:
This is a minor edit
Watch this page
By clicking the "Save page" button, you agree to irrevocably (1) release your contribution under the Creative Commons License NC SA 3.0, (2) allow commercial use of it at the discretion of the website for cost-recovery, and allow a possible future release of the contribution under the CC-BY-SA 3.0 License and the GFDL, and (3) you are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource. Do not submit copyrighted work without permission!
    Editing help (opens in new window)
{{ Infobox diagnosis
| Name      = {{PAGENAME}}
| Image      =
| Width      =
| Caption    =
| Synonyms  =
| Micro      = mixed morphology, +/-papillae, +/-myxoid change
| Subtypes  =
| LMDDx      = [[papillary renal cell carcinoma]], [[unclassified renal cell carcinoma]], [[clear cell renal cell carcinoma]], [[SMARCB1-deficient renal medullary carcinoma]], [[renal mucinous tubular and spindle cell carcinoma]]
| Stains    =
| IHC        = ALK +ve
| EM        =
| Molecular  = ALK rearranagement
| IF        =
| Gross      =
| Grossing  = [[total nephrectomy for tumour grossing]], [[partial nephrectomy grossing]]
| Staging    = [[kidney cancer staging]]
| Site      = [[kidney]] - see ''[[kidney tumours]]''
| Assdx      =
| Syndromes  =
| Clinicalhx =
| Signs      =
| Symptoms  =
| Prevalence = very rare
| Bloodwork  =
| Rads      =
| Endoscopy  =
| Prognosis  =
| Other      =
| ClinDDx    =
| Tx        = may respond to ALK inhibitors
}}
'''ALK-rearranged renal cell carcinoma''', also '''ALK translocation renal cell carcinoma''' and '''ALK-positive renal cell carcinoma''', is a type of [[renal cell carcinoma]] recognized by the World Health Organization (WHO).


==General==
==General==
Michael
49,267

edits

Retrieved from "https://librepathology.org/wiki/Special:MobileDiff/53721"

Navigation menu